StockData

Insmed vs Innoviva

INSM and INVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INSM and INVA compare

Insmed is the larger company, worth 20 times as much as Innoviva ($26.7B against $1.3B).

Insmed grew revenue faster over the last twelve months (240% versus 12.8% for Innoviva).

Innoviva scores higher on the StockData Score (14 against 8 for Insmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINSMINVA
Size and price
Market cap$26.7B$1.3B
Share price$121.86$18.30
Change, 1 year−36.9%−17.8%
Change, 5 years321%8.2%
Beta (5Y)0.840.20
Employees1,664159
StockData Score
Total score814 (better)
Valuation score05 (better)
Growth score3 (better)2
Performance score2 (better)1
Health score36 (better)
Dividend score00
Valuation
P/E–9.3×
P/S17.6×3.0× (better)
P/B36.8×1.2× (better)
EV/EBITDA–5.9×
P/FCF–7.2×
PEG–0.80
FCF yield−2.3%13.8% (better)
Fair value$61.10$30.22
Margin of safety−99.5%39.5% (better)
Growth
Revenue growth (TTM)240% (better)12.8%
Revenue growth, 5Y average29.8% (better)4.1%
EPS growth, 5Y average–10.3%
Profitability
Gross margin84.4% (better)74.5%
Operating margin−37.1%38.8% (better)
Net margin−39.9%–
FCF margin−41.3%41.6% (better)
Return on equity−72.5%–
Return on invested capital–18.0%
Financial health
Debt / equity0.760.23 (better)
Net debt / EBITDA–−1.90
Interest coverage−6.9×8.6× (better)
Current ratio2.8615.44 (better)
Altman Z-score7.42 (better)3.47
Piotroski F-score4–
Dividends and buybacks
Buyback yield–5.9%
Shareholder yield0.00%5.9% (better)
Ownership
Held by institutions102%104%
Held by insiders0.89%5.4%
Insider net buying, 12 months−$133M–
Superinvestors holding1–
Short interest, % of float6.5%11.0%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.